Source: Eur Respir J, 54 (1) 1800353; 10.1183/13993003.00353-2018
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Ian F. Walker, Oumin Shi, Joseph P. Hicks, Helen Elsey, Xiaolin Wei, Dick Menzies, Zhiyi Lan, Dennis Falzon, Giovanni Battista Migliori, Carlos Pérez-Guzmán, Mario H. Vargas, Lourdes García-García, José Sifuentes Osornio, Alfredo Ponce-De-León, Martie van der Walt, James N. Newell. Analysis of loss to follow-up in 4099 multidrug-resistant pulmonary tuberculosis patients. Eur Respir J, 54 (1) 1800353; 10.1183/13993003.00353-2018

Member's Comments

No comment yet.

Related content which might interest you: The radiological spectrum of pulmonary multidrug-resistant tuberculosis in HIV-negative patients Source: Eur Respir J 2005; 26: Suppl. 49, 652s Year: 2005 The radiological spectrum of pulmonary multidrug-resistant tuberculosis in HIV-negative patients Source: Annual Congress 2008 - Imaging of different lung diseases: clinical and experimental observations Year: 2008 The radiological spectrum of pulmonary multidrug-resistant tuberculosis in HIV-negative patients Source: Eur Respir J 2006; 28: Suppl. 50, 13s Year: 2006 Comorbidome in multidrug-resistant tuberculosis patients Source: Virtual Congress 2020 – Tuberculosis and comorbidities Year: 2020 Diagnosis of COPD in patients with multidrug-resistant tuberculosis Source: International Congress 2018 – COPD around the world Year: 2018 Outcome of pulmonary multidrug-resistant tuberculosis Source: Eur Respir J 2007; 30: Suppl. 51, 419s Year: 2007 Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study Source: Eur Respir J 2006; 28: 980-985 Year: 2006 Treatment results of multidrug-resistant pulmonary tuberculosis Source: Eur Respir J 2006; 28: Suppl. 50, 11s Year: 2006 Reducing loss to follow-up during treatment for drug-resistant tuberculosis Source: Eur Respir J, 53 (1) 1802268; 10.1183/13993003.02268-2018 Year: 2019 Characteristics of smear-positive pulmonary tuberculosis patients with delayed diagnosis Source: Virtual Congress 2020 – Non-tuberculous mycobacteria and latent tuberculosis infection Year: 2020 Recurrence after successful treatment among patients with multidrug-resistant tuberculosis Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis Year: 2011 Prevalence of MDR and XDR tuberculosis among patients with failure of re-treatment course Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008 Evaluation of relapse and defaulter pulmonary tuberculosis patients Source: Eur Respir J 2005; 26: Suppl. 49, 647s Year: 2005 Epidemiological features of nosocomial tuberculosis in patients with pulmonary tuberculosis in TB hospital Source: International Congress 2018 – Tuberculosis transmission and screening strategies Year: 2018 Analysis of pulmonary and extra-pulmonary tuberculosis patients registered in a local dispensary Source: Eur Respir J 2004; 24: Suppl. 48, 417s Year: 2004 Effectiveness of chemotherapy in newly detected patients with pulmonary tuberculosis with poly-resistance Source: Annual Congress 2010 - Tuberculosis drug resistance Year: 2010 Management of multidrug-resistant tuberculosis and patients in retreatment Source: Eur Respir J 2005; 25: 928-936 Year: 2005 Delays in diagnosis and treatment of patients with smear-positive pulmonary tuberculosis Source: Eur Respir J 2005; 26: Suppl. 49, 689s Year: 2005 Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid Source: Eur Respir J 2015; 45: 1498-1501 Year: 2015 Follow-up and treatment of patients who were diagnosed multidrug resistant tuberculosis Source: Eur Respir J 2006; 28: Suppl. 50, 11s Year: 2006